Docusign Envelope ID.. 9F2149Ftk322F4E6D-BA66-906B3BDECF3D
Company Registered Number., 02685083
Charity Registered Number (England & Wales): 1009671
NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)
UNAUDITED
TRUSTEES. REPORT AND FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023

Docusign Envelope ID.. 9F2149Ftk322F4E6D-BA66-906B3BDECF3D
NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee
CONTENTS
Page
Reference and Administrative Details of the Charity. its Trustees and Advisers
Trustees, Report
2-11
Statement of Trustees. Responsibilities
12
Independent Examine¢s Report
13
Consolidated Statement of Financial Activities
14
Consolidated Balance Sheet
15-16
Charity Balance Sheet
17-18
Consolidated Statement of Cash Flows
19
Notes to the Financial Statements
20-44

Docusign Envelope ID.. 9F2149Ftk322F4E6D-BA66-906B3BDECF3D
NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)
REFERENCE AND ADMINISTRATIVE DETAJLS OF THE CHARITY. ITS TRUSTEES AND ADVISERS
FOR THE YEAR ENDED 31 DECEMBER 2023
Trustees
Stephen Pugh. Chair
Hannah Kun￿Ik
Professor Celia Moss OBE
Bharat Pandya (resiqned 31 December 2023)
James Pitayanukul, Treasurer
Hedwig Vollers
Suzanne Watson
Company registered
number
02685083
Charity registered
number
1009671
Registered office
11 Murray Street
London
NW19RE
Chief executive officer & Andrew Proctor
Company secretary
Independent Examiner
MHA
Chartered Accountants
MHA House
Charter Court
Swansea Enterprise Park
Swansea
SA7 9FS
Principal Bankers
CAF Bank Ltd
National Westminster Bank plc
BarclayB Bank plc
Status and Governing
Document
National Eczema Society is a charitsble company, limited by guarantee. It was
incorporated on 6 February 1992 and registered as a charity on 10 March 1992. It
is governed by its Articles of Association.
Subsldlary Companles
Eczema Trading Limited
Page 1

Docusign Envelope ID.. 9F2149Ft￿322F4E6D-BA66-906B3BDEcF3D
NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)
TRUSTEES. REPORT
FOR THE YEAR ENDED 31 DECEMBER 2023
The trustees present their annual report together with the financial statements of the Group and the Charity for
the year 1 January 2023 to 31 December 2023. The trustees confirm that the Annual Report and financial
statements of the company comply with the current statutory requirements. the requirements of the company's
goveming document and the provisions of the Statement of Recommended Practice ISORP), applicable to
charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and
Republic of Ireland (FRS 102). Since the Charity and Ihe Group qualifies as small under section 383, the
stralegic report required of medium and large companies under The Companies Act 2006 (strategic Report and
Director's Report) Regulations 2013 is not required.
Purpose and aims
National Eczema Society was established in 1975 to support people with eczema and their families and to work
on their behalf. We remain dedicated to these founding principles and today we continue to help people across
the UK by providing evidence-based information and advice about eczema and its management. We deliver
this in various ways through our website. webinars. instructional videos, social media communications and
publications. We also provide a collective voice for people with eczema. to inform research and influence health
policy to improve eczema care, and raise greater awareness and understanding of the condition among people
affected by eczema and the wider public.
The prevalence of eczema has increased over recent decades, and around one in five children and one in ten
adults are now impacted by this life-challenging condition in the UK. While the reasons for the increase are not
fully understood, it does mean the charity's work is needed more than ever. There is as yet no cure for eczema
and, unless you have the condition, it can be hard to understand the daily challenge of living with relentless
itching and inflamed, painful skin. Many heallhcare professionals have limited dermatology training and timely
access to specialist dennatology healthcare for people with eczema can often be difficult. National Eczema
Society aims to provide the infomiation and support needed for people to self-manage their eczema effectively.
to become experts in their own care, leam from the eXperIen￿S of others, and provide the reassurance of
knowing they are not on their own.
Ensuring our work delivers our charitable aims
We review our activities each year and monitor the impact of our work to ensure we continue to fulfil our
purpose of supporting people affected by eczema. Among other ways, we assess the Society's performance
and achievements through the number of people we have helped with infonnation and advice. and the quality
and consistency of the resources we provide.
We consider how planned activities will contribute to the aims and objectives we have set, and in doing this we
have referred to the Charity Commission's general guidance on public benefit. We have had regard to the
legislative and regulatory requirements for disclosing how our charitable objectives have provided such benefit,
and complied with the duty set out in section 4 of the Charities Act 2011.
2023 Activity and achievements- delivering public benefit
All our charitable activities focus on supporting people affected by eczema and championing their needs, and
further our charitsble purposes for the public benefit. Here we present a summary of the Society's work over
the year.
Page 2

Docusign Envelope ID.. 9F2149Ft￿322F4E6D-BA66-906B3BDEcF3D
NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)
TRUSTEES. REPORT
FOR THE YEAR ENDED 31 DECEMBER 2023
Delivering information and advice for people living with eczema
The Society continues to provide a wide range of high quality. evidence-based information and advice about
eczema and its management for the UK eczema community.
We produ￿ a wide range of patient information booklets and faclsheets about eczema management and
treatment. available online and in print. We distribute printed copies at events the charity organises and
attends, and we provided over 17,500 copies of our printed publications to healthcare professionals during the
year, for onward distribution to patients in hospital dermatology clinics and other healthcare settings.
National Eczema Society factsheets and booklets are updated regularfy on a rolling review cycle and checked
by healthcare professionals to ensure the infonnation is accurate and up-to-date. We updated and reprinted a
number of publications over the year, including our Itching and Scratching booklet, Living with Eczema (Adults)
booklet, and Paste Bandages and Wet Wraps booklet.
All our eczema infomiation is made available on the Societys website. which received over two million visits
during the year. It is difficull to compare year-on-year activity because Google changed the way website activity
is recorded with Google Analytics Version 4 in July 2023. Webpages on facial eczema. emollients, eye and ear
eczema, hand eczema, topical steroid treatments, topical steroid withdrawal, pompholyx eczema and scalp
eczema remain especially popular. We also promote health advice messages through our social media
channels, media engagement and other extemal communications. We continued our programme of webinars,
working in partnership with St John's DermAcademy (part of Guy's and St Thomas, Hospital, London) to jointly
deliver events, one focusing on new treatments for more severe eczema and the other exploring eczema
and the mind-skin connection. Recordings of several past webinars are available to view on the Society's social
media pages.
During this period 12023. our eczema helpline provided personalised independent advice for people struggling
to cope with eczema wherever they live in the UK. We re￿iVed around 1,300 telephone, email and message
enquiries a year from parents of children with eczema and adults living with the condition. We offered a
dermatology nurse call-back service for people who had more complex enquiries, and around 40 % of callers
were helped by one of our experienced dermatology nurse advisers. Our Helpline was available free of charge
to anyone affected by eczema in the UK who needs our support. Please note that the Society took the decision
to stop offering a helpline service in March 2024. as part of a wider strategic change prograrnme to increase
our work supporting eczema research and campaigning for improved eczema care for the eight million adults
and children affected by the condition in the UK.
We continue to raise awareness of local volunteer-led patient support groups, by providing infonnation and a
presence for these groups on the Society's website. The West Surrey and North-East Hampshire Support
Group held a number of fundraising events over the year and organised an infomiation day in Guildford in
February on the 'Combineé Approach, to managing eczema. Dr Alpa Kanji talked about how habit reversal
therapy combined with topical treatments can help people with eczema break the habitual itch-scratch cycle. Dr
Kanji is a dermatologist working at St John's Institute of Dermalology in London and she teaches habit reversal
therapy. The event was livestreamed and recorded on Fa￿boOk. so many more people with eczema could
access the talk.
Our planned work to develop an online forum to provide peer support for people affected by eczema was not
taken forward again this year because of competing pressure on charity resources.
Page 3

Docusign Envelope ID.. 9F2149Ft￿322F4E6D-BA66-906B3BDEcF3D
NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)
TRUSTEES. REPORT
FOR THE YEAR ENDED 31 DECEMBER 2023
NES membership scheme
National Eczema Society is a membership organisation and we are very grateful to our 2,000 members who
support the Society through their annual membership fee and additional donations. Members receive our
membership magazine Exchange. which features expert information and news about eczema. Members are
also encouraged to attend the Society's Annual General Meeting and conlribute their ideas on the running of
the charity. As in previous years. support for our charity extends far beyond our membership and we remain
grateful to all our donors, and to those members who continue to support us financially even though they no
longer have any personal need of our help.
Income from the membership scheme has fallen as the number of members has gradually declined over the
years. We took the difficult decision to move to producing issues of Exchange magazine starting in 2024,
replacing the previous quartedy publishing schedule. so that costs are better aligned with membership income.
Supporting eczema research
We continue to support patient involvement in shaping research. NES is approached regularly by researchers
seeking patient views and to learn from patient experiences. It is so encouraging to see such a range of
research underway and new treatments in the pipeline, following a long period when eczema was largely
overlooked. The Society is actively supporting eczema research by participating in study steering groups,
providing patient perspectives for research projects. promoting surveys, supporting patient recruitment for trials,
and working with universities and companies that are assessing and developing new drug treatments. We do
this to help ensure eczema research has the greatest chance of success in finding new treatments and
ultimately a cure. Projects supported during the year include:
A-STAR - UK-Irish Atopic Eczema Systemic Therapy Register
BEACON trial
Best systemic treatments for adults with atopic eczema over the long term
BEACONomics- study embedded within the BEACON trial investigating how eczema treatments worf(
BIOMAP Innovative Medicines Initiative - Biomarkers in Atopic Dermatitis and Psoriasis
ECO trial - Eczema Care Online
END-ITCH study - Eczema and Dermatitis, Implementing the Combined Approach
Global Patient Initiative for Optimal Eczema Care
Kids in Control study
Navigating Primary Care with Topical Steroid Withdrawal
RAPID Eczema Trials Programme
SLEEP study- Supporting children's sleep in those with Eczema Programme
TECH study- Teleconsultations for Eczema in Children
TRANS-FOODS study - preventing peanut allergy
National Eczema Society staff and trustees contributed to several arlides in academic journals over the year,
including the following published in 2024=
Do people with eczema and their carers understand topical steroid potency? Results of two surveys., Celia
Moss et al, Clinical and Experimental Dennatology. Volume 49. Issue 3. March 2024. Pages 267-270,
htt s.Ildoi.or
110.10931cedlllad372
Linked to the above paper, Professor Celia Moss presented an abstract on this topic at the British Society for
Paediatric Adolescent Dem)atology session at the 103rd Annual Meeting of the British Associalion of
Dermatologists in Liverpool in June.
Page 4

Docusign Envelope ID.. 9F2149Ft￿322F4E6D-BA66-906B3BDEcF3D
NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)
TRUSTEES. REPORT
FOR THE YEAR ENDED 31 DECEMBER 2023
NES provides a patient perspective for clinical guideline development, the assessment of new eczema
treatments. and policy consultations. During the year, we contributed to the assessment by the National
Institute of Health and Care Excellence (NICE} of a new monoclonal antibody drug called Lebrikizumab. This in
new treatment for moderate to severe eczema. As eczema affects people in different ways, it is important that
we have a range of NHS treatment options to help ensure people can access a treatment that works effectively
for them.
Improving eczema care
The charity undertakes a range of activities to raise awareness and understanding of eczema among the
general public, and to promote the information and advice the Society provides for people living with eczema
and their families.
The Society launched a major campaign in May 2023, calling on the UK medicines regulator, the MHRA, to
introduce clearer strength labelling of steroid creams and ointments. We are asking the MHRA to mandate
clear potency labelling on topical steroid (TCS) tubes, packaging and patient information leaflets.
Topical steroids are used by millions of adults and children in the UK to Ireat or prevent eczema flare-ups. It is
important patients and their carers have the right information to use these medicines safely and effectively to
manage eczema well. Topical steroids are effective treatments for eczema but, like many treatments, they can
have side effects. People with eczema and carers are understandably Con￿rned about overusing TCS. We
believe clear potency labelling will help improve patient understanding and confidence in these widely-used
medicines.
This initiative has strong support from the eczema community. National Eczema Society conducted an online
survey in January 2023. to find out more about people's knowledge and understanding of steroid potency. We
received 943 responses, from both adults with eczema and parents of children with eczema, and many thanks
to everyone in the eczema community who took part. Some 95°h of respondents said they want to see clear
strength labelling on all steroid creams and ointments.
This call for clearer labelling also has strong support from healthcare professionals and other charities, which
endorsed this Society-led initiative. We are in dialogue with the MHRA about the campaign and are hopeful of a
successful outcome.
In other work, the Society has contributed to MHRA reviews of topical steroid withdrawal reactions and
welcome the MHRA guidance on this.
Representlng patient vlews
As a national patient organisation for the eczema community, the Society plays a leading role in providing a
collective voice to champion the needs of those affected by the condition. We seek lo improve health outcomes
for people with eczema by influencing health policy and participating in groups like the Dermatology Council for
England and working with professional bodies like the British Association of Demiatologists (BAD) and Primary
Care Dermatology Society (PCDS). As a member of the steering group, we contributed to the major NHS
England Dermatology Outpatient Transfomiation Programme. which developed a range of new guidance to
help dermatology healthcare providers meet the challenges of responding to service funding pressures.
Patient interest and awareness of the side effects of topical steroid medication, and concems about topical
steroid withdrawal ITSW), continues to grow. NES remains active in this area, building on our earlier work wilh
the British Association of Dermatologists to develop a position statement on TSW, and our contribution to the
MHRA review of topical steroid withdrawal reactions. Topical steroid withdrawal is complex and research into
the causes. symptoms and treatments is limited. NES wants to see more research in this area, to support
evidence-based diagnosis and treatment approaches.
Page 5

Docusign Envelope ID.. 9F2149Ft￿322F4E6D-BA66-906B3BDEcF3D
NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)
TRUSTEES. REPORT
FOR THE YEAR ENDED 31 DECEMBER 2023
One of the challenges is that the symptoms people experience when stopping using topical steroids can appear
similar to those of poorly controlled eczema. These symptoms can be very painful and distressing. The Society
is emphasising the Importan￿ of using topical steroid treatments safely and effectively, and among other
things is calling for clearer labelling of topiGal steroids to show their potencylstrength.
National Eczema Week
Our goal for National Eczema Week 2023 was to raise awareness of the impact of eczema on patients. mental
health. This is not widely recognised or understood outside the eczema community. We encouraged people to
open up and start a conversation about living with eczema, sharing their experiences of the emotional, social
and personal impacts of eczema.
We produced a powerful video for the campaign entitled 'More than just an itch,. funded by corporate partner
Sanofi. The short-form documentary-style video focussed on the experiences of five people with eczema, and
how the condition has affected them. The videos received over 1.500 views. with 85 hours of watched content.
We also produced a series of podcasts to support the campaign. featuring both patients and healthcare
professionals talking about the emotional impacts of eczema and approaches for supporting our mental health.
The podcast has been downloaded and viewed over 700 times. All the videos and podcasts are available to
view on the Society's YouTube channel.
We achieved national media profile for the campaign, with 32 items of coverage including two national media
hits (The Independent online and Moming Live). Total potential audience reach with the campaign messaging
was over 33 million.
Overall, on social media. the campaign videos re￿iVed over 35,000 total views, with a 2.5 % engagement rate
on Facebook and 1.2/0 on Instagram. x￿wItter generated the highest engagement rate at 3.3%. Special
thanks to our influencer partners Nicola Johnson and Katie Mackie for producing content to support the
campaign, which generated positive engagement.
During National Eczema Week we held the 'Eczema and the Mind-skin Connection, webinar, jointly wilh St.
John's DermAcademy, which aligned closely with our campaign theme. Over 100 people attended the webinar.
Media and social media engagement
The Society provided press comment for a number of eczema stories in the media over the year. We
contributed to stories about managing eczema in cold weather for BBC Morning Live and BBC Online, as well
as coverage in the Mail of Sunday, The Times and i newspaper on topics ranging from waiting times for
dermatology appointments lo new treatments for eczema. Society supporter Ellen Vincent was featured in a
major article in the Mail on Sunday about a forthcoming new treatment for more severe eczema called
lebrikizumab. The Society was also featured in several professional publications including pharmacy
publications. The Society was approached for media comment about topical steroid withdrawal during the year
and we were mentioned in features on this topic produced by the BBC and ITV. Capacity constraints and
Gompeting priorities continue to impact on the proactive media work we are able to undertake.
We continued lo grow our social media reach and activity during the year. reflecting how people increasingly
seek and share infom)ation about eczema. The Society now has over 25,000 followers on Facebook, an
increase of around 1,400 over the year. We also grew our following on x￿wItter to over 8,500. and almost
12,000 on Instagram by the end of 2023.
Page 6

Docusign Envelope ID.. 9F2149Ft￿322F4E6D-BA66-906B3BDEcF3D
NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)
TRUSTEES. REPORT
FOR THE YEAR ENDED 31 DECEMBER 2023
Growing income and building financial sustainability
We continue to commit resources to income generation. to achieve our charitable objectives and build future
financial sustainability- We are immensely grateful to our thoughttul and generous supporters who choose to
leave a gift to National Eczema Society in their Will. Income from legacies was higher in 2023 and this
significantly impacls our overall income.
We continue to develop partnerships with companies that share our values and are willing to support our work
and engage in joint education and awareness-raising activity. During the year we worked with Abbvie, Almirall,
Aspire Phamia, Bioderma, Dermal Laboratories, Lilly, LEO Phamia and Sanofi.
There were many fundraising highlights during the year. Income from challenge events, including the London
Marathon and Great North Run, was strong in 2023 and we thank all our supporters for raising funds and
awareness of eczema by participating in events like these. We continue to find it challenging securing grants
from charitable trusts and foundations.
The Society's West Surrey and North-East Hampshire Support Group undertook various local fundraising
activities around Guildford. and presented a cheque for £2,000 at the Annual General Meeting in September.
The Society's members and donors generously supported our summer and Christmas fundraising appeals
once again and we are grateful to everyone who supported the Society in dirterent ways with their donations
over what has been a challenging year with costwof-living pressures.
Organisational development
During the year, we continued our work preparing for the Society's office move. The lease on the charity's
current office expires in March 2025 and future provision needs to take into account the changing needs of the
charity following the introduction of hybrid working a￿angeMents.
Strategy work undertaken induded refining the Socievs vision, mission and values and scoping work to
refresh the charity's brand and visual identty- We have also positioned our charitable work into three core
areas..
Provide infomiation and advice
Improve eczema care
Support eczema research
2024 Plans and development priorities
Looking ahead, we aim to ensure National Eczema Society continues to achieve the greatest impact we can for
members and the UK eczema community. The charity's wre charitable work will continue, as well as laking
forward strategically important activity including growing our support for eczema research and strengthening
our work to improve eczema care. We plan to conduct a strategic review in 2023124 that will potentially change
the focus of some areas of National Eczema Society's work.
Page 7

Docusign Envelope ID.. 9F2149Ft￿322F4E6D-BA66-906B3BDEcF3D
NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)
TRUSTEES. REPORT
FOR THE YEAR ENDED 31 DECEMBER 2023
Development priorities for 2024 include-
Providing inforniation and advice
Continue providing high-quality eczema information and advice, through the websile, printed
publications. webinars and other channels.
Scope and develop resources to highlight the impact of eczema on people's mental health and
emotional well-being.
Introduce a regular monthly e-newsletter for NES stakeholders.
Scope and plan an NES-moderated online forum and closed Facebook group.
Improving eczema care
Increase public awareness and understsnding of the challenges of living with eczema, highlighting the
impacl on people's physical. mental health and quality of life.
Lead the annual national flagship awareness event. National Eczema Week in September.
Lead a coalition campaigning for clearer potency labelling of topical steroids.
Continue to call for more research into diagnosis and treatment of topical steroid withdrawal.
Contribute patient perspectives to dinical guideline development and the assessment of new treatments
and policy consLbltations. working with regulatory bodies including the MHRA. NICE and the SMC.
Supporting eczema research
Scope options for developing an NES research grant programme, to fund studentships and innovation
grants for eczema research.
Recruit a panel of people with eczema to share their experiences of living with the condition with
researchers.
Continue to contribute patient insights for major eczema research projects and programmes.
Page 8

Docusign Envelope ID.. 9F2149Ft￿322F4E6D-BA66-906B3BDEcF3D
NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)
TRUSTEES. REPORT
FOR THE YEAR ENDED 31 DECEMBER 2023
Financial Results
The Society planned to achieve a budget surplus in 2023. made possible largely by higher legacy income. This
is in Gontrast to the loss recorded the previous year.
Income for the year was £497,252, with expenditure al £477,562, generating an annual surplus of £19,698.
This compares with a deficit of £70.621 in the year ended 31 December 2022. At 31 December 2023, the
Society had reserves of £670,7671£651,070).
We would like to thank the many people who, as in previous years, by joining or renewing their membership,
supporting our appeals and fundraising in a variety of often innovative ways, have enabled us to continue our
work. The efforts and contribution of supporters and volunteers is invaluable to the Society. We are grateful
also to those who remembered the Society in their Wills, the charitable trusts and companies that have
supported us during the year. and to all the healthcare professionals who have provided us with so much time.
advi￿ and support especially members of the Medical Advisory Board.
Reserves Pollcy
The trustees aim to maintain adequate reserves to pemiit the ongoing operations of the charity- In arriving at
their assessment of a suitable limit, trustees have considered the predictability of the Society's income and the
nature of its expenditure, together with the degree to which these are committed. Legacies form an important
part of the Society's income, and whilst legacies can often be substantial relative to overall income, they are
unpredictable and historical trends show there can be periods of years where this source of income is much
lower than the long-term average. Expenditure. on the other hand. is more consistent and predictable.
Trustees last reviewed the ReseNes Policy in 2022. and consider that holding unrestricted reseNes equal to
approximately six months unrestrided charitable expenditure would be sufficient to close or merge the charity,
should this ever be necessary. However. given the known volatility of legacy income. trustees have detemined
a reseNes target of 12 months, future overheads expenditure is more appropriate to respond to fluctuations in
income.
In order to make unrestricted reserves more transparent, fijnds that are not readily available to spend are held
in reserves designated for specific purposes. A key aim of the Society is to promote research into the causes
and treatment of eczema. This being so, the trustees have designated a proportion of reserves to fund future
research activity. in addition to any funds that donors have specifically restricted for this purpose. Funds that
are not readily available to spend, notably those represented by fixed assets, are held in a reserve designated
for this purpose. The pension reserve shows future deficit payments owed in relation to an historical defined
benefit pension scheme (see note 19).
The balance held in unrestricted funds at 31 December 2023 is £664.01612022: £644,319). Unrestricted funds
include funds tied up in tangible assets of £12,903 (2022.. £19,721), the pension reserve of1£4,5671 (2022..
1£8.587)l and designated Research funds of £110.000 12022: £110.0001. The remaining general funds of
£545,680 (2022= £523,185) are materially in line with the chariws reserves policy target of 12 months future
overheads expenditure, budgeted at £530.000 for the 2024 financial year.
Page 9

Docusign Envelope ID.. 9F2149Ft￿322F4E6D-BA66-906B3BDEcF3D
NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)
TRUSTEES. REPORT
FOR THE YEAR ENDED 31 DECEMBER 2023
Risk Management
The trustees have taken steps to identify and address major risks facing the Society. including maintaining a
risk register. The principal uncertainty in respect to the Society's future is the ability to maintsin sufficienl
income to deliver the charity's operations, and ensure the Society has adequate resources lo comply with
regulatory changes affecting the voluntary seclor. Greater focus and investmenl are being directed to
fundraising activities. to ensure the Society generates sufficient income each year to fund planned activities.
This includes building sustainable sources of non-legacy income.
The principal risk of financial sustainability for the charity is dosely monitored by the trustees on a regular
basis, including reviewing management accounts at quarterfy Board meetings. Attention also continues lo focus
on non-financial risks including reputation, health and safety, security, confidentiality and data protection, which
are supported by appropriate policies and procedures as well as management updates as needed.
The Trustees and Organisation
The Society is a charitable company. Although called trustees. we are the directors of the company for the
purposes of company law. The trustees who served during the year and up to the date of this report are given
onpage1.
The Society's governance processes are set out in its Articles of Association. The Board of Trustees
administers the Society, which meets routinely four times a year and additionally as circumstances demand. A
chief executive is appointed by the trustees to manage the day-t(Hlay operations of the Society within a
framework agreed by the Board.
There must be a minimum of three trustees bLrt there is no maximum number. and trustees must be elected by
the members of the Society at its Annual General Meeting (AGM). Trustees may be co-opted onto the Board
during the year and must then stand for election by the members at the next AGM. At least a third of truslees
are required lo retire from office each year but may, if they wish, offer themselves for re-election al the AGM.
Trustees are recruited through the Society's membership, local support groups, other eczema community
networks and open advertising. In seeking trustees, the Society has regard of the need to ensure that the
Trustee Board has an appropriate range of professional skills and experience, reflects our commitment to
diversity, and also that trustees are drawn from different areas of the UK.
Although not constitutionally binding. the Society wishes to work towards aligning with the Charity Govemance
Code, which recommends trustees serve fixed terms in office. The guidance recommends trustees serve an
initial three-year temi. with the possibility of being reelected by members for a further three-year period.
Trustees in particular roles {e.g. Chair, Treasurer) could serve a longer nine-year period, subject to formal
review. One current trustee has served longer than nine years and provides specific professional skills to the
Board. As yet, it has not been possible to find a replacement with comparable expertise.
New trustees are provided with an introduction pack, which includes the Society's governing documents, copies
of the past year's accounts, and a briefing on their duties and responsibilities and of the Society's governance
processes. Prior to joining the Board. new trustees will usually attend at least one Board meeting in an observer
Gapacity, which gives them the opportunity to meet the trustees and chief executive.
Trustees receive no remuneration and no trustee has a beneficial interest in any of the group companies.
Page 10

Docusign Envelope ID.. 9F2149Ft￿322F4E6D-BA66-906B3BDEcF3D
NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)
TRUSTEES. REPORT
FOR THE YEAR ENDED 31 DECEMBER 2023
The Society has a Medical Advisory Board IMAB). comprised of healthcare professionals who act in an
advisory and ambassadorial capacity for the charity- Members volunteer their time and are all experienced
healthcare professionals who work in the field of dermatology, and who have a particular professional interest
in eczema management and research. The MAB is chaired by National Eczema Society trustee, Professor
Celia Moss OBE.
The trustees set the remuneration of the chief executive and approve the remuneration of other Society stsff.
Remuneration levels are based on research of similar roles in the sector and benchmark salary data.
The Trustees Report has been prepared in accordance with the provisions applicable to entities subject to the
small companies regime.
This report was approved by the Board of Trustees on signed on their behalf by:
3vJned by..
3E26469DD84CW:..........
Stephen Pugh
Chair
September 25, 2024
Page11

Docusign Envelope ID.. 9F2149Ftk322F4E6D-BA66-906B3BDECF3D
NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)
STATEMENT OF TRUSTEES. RESPONSIBILITIES
FOR THE YEAR ENDED 31 DECEMBER 2023
The Trustees (who are also the directors of the Charity for the purposes of company law) are responsible for
preparing the Trustees, Report and the financial stalements in accordance with applicable law and United
Kingdom Accounling Standards (United Kingdom Generally Accepted Accounting Practice).
Company law requires the Trustees to prepare financial statements for each financial year. Under company law,
the Trustees must not approve the financial statements unless they are satisfied that they give a true and fair
view of the state of affairs of the Group and the Charity and of their incoming resources and application of
resources, including their income and expenditure. for that period. In preparing these financial statements. the
Trustees are required to..
select suitable accounting policies and then apply them consistently.
observe the methods and principles of the Charities SORP (FRS 1021-
make judgements and accounting estimates that are reasonable and prudent-
stale whether applicable UK Accounting Standards IFRS 102) have been followed, subject to any material
departures disclosed and explained in the financial statements;
prepare the financial statements on the going concem basis unless it is inappropriate to presume that the
Group will continue in business.
The Trustees are responsible for keeping adequate accounting records that are sufficient to show and explain
the Group and the Charity's transactions and disclose with reasonable accuracy at any time the financial position
of the Group and the Charity and enable them to ensure that the financial statements comply with the
Companies Act 2006. They are also responsible for safeguarding the assets of the Group and the Charity and
hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.
Approved by order of the Members of the Board of Trustees and signed on its behalf by-
Stqned by..
en
Chair
Date: September 25, 2024
Page 12

Docusign Envelope ID.. 9F2149Ftk322F4E6D-BA6&906B3BDECF3D
NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)
INDEPENDENT EXAMINER'S REPORT
FOR THE YEAR ENDED 31 DECEMBER 2023
Independent Examinerfs Report to the Trustees of National Eczema Society ('the Group.)
I reporl to the Charity Trustees on my examination of the consolidated accounts of the Group, set out on pages
14 to 45, comprising the National Eczema Society {'the parent Charity) and its subsidiary undertakings for the
year ended 31 December 2023.
Responslbllltles and Basls of Report
As the Trustees of the parent Charity (and its directors for the purposes of company lawl you are responsible for
the preparation of the consolidated accounts of the Group in accordance wtih the requirements of the
Companies Act 2006 {'the 2006 Act.).
Having satisfied myself that the consolidated accounts are not required to be audited under Part 16 of the 2006
Act and are eligible for independent examination, I report in respect of my examination of the Group's accounts
as carried out under section 145 of the Charilies Act 2011 ('the 2011 Act.). In carrying out my examination I have
followed the Directions given by the Charity Commission under section 145{5)(b) of the 2011 Act.
Independent Examiner's Statement
Since the Group's gross income exceeded £250,000 your examiner must be a member of a body listed in
section 145 of the 2011 Act. I confirm that l am qualrfied to undertake the examination because l am a member
of the Institute of Chartered Accountants in England and Wales. which is one of the listed bodies.
I have completed my examination. I confimi that no matters have come to my attention in connection with the
examination giving me Cause to believe in any material respect..
accounting records were not kept in respect of the parent Charity and its subsidiaries as required by
section 386 of the 2006 Act., or
the accounts do not accord with those records., or
the accounts do not comply wth the accounting requirements of section 396 of the 2006 Acl other than
any requirement that the accounts give a 'true and fair. view which is not a matter considered as part of
an independent examination- or
the accounts have not been prepared in accordance with the methods and principles of the Statement of
Recommended Practice for accounting and reporting by charities applicable to charities preparing their
accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of
Ireland IFRS 102).
I have no concerns and have come across no other matters in connection with the examination to which
attention should be drawn in this report in order to enable a proper understsnding of the accounts to be reached.
Signed:
Dated: September 25, 2024
Rachel Doyle ACA FCCA DChA
MHA
Chartered Accountants
MHA House
Charter Court
Swansea Enterprise Park
Swansea
SA7 9FS
Page 13

Docusign Envelope ID.. 9F2149Ftk322F4E6D-BA66-906B3BDECF3D
NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)
CONSOLIDATED STATEMENT OF FINANCIAL ACTIVITIES (INCORPORATING INCOME AND
EXPENDITURE ACCOUNT)
FOR THE YEAR ENDED 31 DECEMBER 2023
Unrestricted
tunds
2023
Restricted
funds
2023
Total
funds
2023
Total
funds
2022
Note
Income from:
Donations and legacies
Other trading activities..
Income from fundraising
Income from trading activities
Investments
481.158
481.158
327,075
5,732
2.965
7.397
5,732
2.965
7,397
10.205
4,109
1,432
Total income
497.252
497,252
342,821
Expenditure on:
Raising funds
Charitable activities
71.317
406.245
71.317
406,245
64,906
348,853
Total expenditure
477.562
477,562
413,759
Net movement in funds before other
recognised gains
19.690
19,690
170,938)
Other recognised gainsl(losses):
Gainsl(losses) on pension scheme
317
Net movement in funds
19,698
19,698
170,621)
Reconciliation of funds:
Total funds brought forward
Net movement in funds
644,319
19.698
6,751
651,070
19.698
721.691
170,621)
Total funds carrled forward
664,017
6,751
670,768
651.070
The Consolidated Statement of Financial Activities includes all gains and losses recognised in the year. All
income and expenditure derive from continuing activities.
The notes on pages 20 to 44 fomi part of these financial statements.
Page 14

Docusign Envelope ID.. 9F2149Ftk322F4E6D-BA66-906B3BDECF3D
NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)
REGISTERED NUMBER: 02685083
CONSOLIDATED BALANCE SHEEr
AS AT 31 DECEMBER 2023
2023
2023
2022
2022
Note
Fixed assets
Intangible assets
Tangible assets
14
1.462
10,733
1,836
17.885
15
12,195
19,721
Current assets
Debtors- Amounts falling due within one year
Cash at bank and in hand
17
88.906
728,799
65,445
687,108
817.705
752,553
Creditors= Amounts falling due within one
year
18
(158,773)
1116.940)
Net current assets
658,932
635,613
Total assets less currenl liabilities
671,127
655,334
Creditors= Amounts falling due afler more
than one year
19
{360)
(4,264)
Total net assets
670,767
651.070
Group funds
Restricted funds
20
6,751
664.016
6.751
644,319
Unrestricted funds
20
Total funds
670,767
651,070
Page 15

Docusign Envelope ID.. 9F2149Ftk322F4E6D-BA66-906B3BDECF3D
NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)
REGISTERED NUMBER: 02685083
CONSOLIDATED BALANCE SHEEf (CONTINUED)
AS AT 31 DECEMBER 2023
The Charity was entitled to exemption from audit under section 477 of the Companies Act 2006.
The members have not required the company to obtain an audit for the year in question in accordance with
section 476 of Companies Act 2006.
The Trustees acknowledge Iheir responsibilities for complying with the requirements of the Act with respect to
accounting records and preparation of financial statements.
The financial statements have been prepared in accordan￿ with the provisions applicable to entities subject to
the small companies regime.
The financial statements were approved and authorised for issue by the Trustees and signed on their behalf by..
3vJned by..
(gtyffi...Pts4.....................
3È
6t169D
Stepken Wug
Chair
Date: September 25, 2024
The notes on pages 20 to 44 fonn part of these financial statements.
Page 16

Docusign Envelope ID.. 9F2149Ftk322F4E6D-BA66-906B3BDECF3D
NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)
REGISTERED NUMBER: 02685083
CHARITY BALANCE SHEET
AS AT 31 DECEMBER 2023
2023
2023
2022
2022
Note
Fixed assets
Intangible assets
Tangible assets
Investments
14
1.462
10,733
100
1,836
17.885
100
15
16
12,295
19.821
Current assets
Debtors: Amounts falling due within one year
Cash at bank and in hand
17
154,841
581,497
132,652
647.525
736,338
780,177
Creditors: Amounts falling due within one
year
18
(115.791)
(115,140)
Net current assets
620,547
665.037
Total assets less current liabilities
632,842
684,858
Creditors: Amounts falling due after more
than one year
19
(360)
{4,264}
Total net assets
632,482
680.594
Charity funds
Restricted funds
20
6.751
625,731
6,751
673,843
Unrestricted funds
20
Total funds
632,482
680,594
Page 17

Docusign Envelope ID.. 9F2149Ftk322F4E6D-BA66-906B3BDECF3D
NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)
REGISTERED NUMBER: 02685083
CHARITY BALANCE SHEET (CONTINUED)
AS AT 31 DECEMBER 2023
The Charity's net movement in funds for the year was £(48.112) (2022 - £(69,7281).
The Charity was entitled to exemption from audit under section 477 of the Companies Act 2006.
The members have not required the company to obtain an audit for the year in question in accordan￿ with
section 476 of Companies Act 2006.
The Trustees acknowledge their responsibilities for complying with the requirements of Ihe Act with respect to
accounting records and preparation of financial statements.
The financial statements have been prepared in accordan￿ with the provisions applicable to entities subject to
the small companies regime.
The financial statements were approved and authorised for issue by Ihe Trustees and signed on their behalf by..
5vJned by..
en
Chair
Date: September 25, 2024
The notes on pages 20 to 44 fonn part of these financial statements.
Page 18

Docusign Envelope ID.. 9F2149Ftk322F4E6D-BA66-906B3BDECF3D
NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)
CONSOLIDATED STATEMENT OF CASH FLOWS
FOR THE YEAR ENDED 31 DECEMBER 2023
2023
2022
Note
Cash flows from operating activities
Net cash used in operating activities
38.315
36,416
Cash flows from Investing actlvltles
Investment income
7,397
(2,021)
(2,000)
1.432
Purchase of intangible assets
Purchase of tangible fixed assets
Net cash provided by investing activities
3,376
1,432
Change in cash and cash equivalents in the year
Cash and cash equivalents at the beginning of the year
41,691
37,848
687,108
649.260
Cash and cash equivalents at the end of the year
23
728,799
687,108
The notes on pages 20 to 44 form part of these financial statements
Page 19

Docusign Envelope ID.. 9F2149Ftk322F4E6D-BA66-906B3BDECF3D
NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023
General infonnation
National Eczema Sociely is a charitable company limited by guarantee and is registered with the Registrar
of Companies (Company Registered Number- 02685083). the Charity Commission in England and Wales
(Charity Registered Number= 1009671).
In the event of the Charity being wound up. the liability in respect of the guarantee is limited to £1 per
Member of Ihe Charity.
The address of the registered office is given in the Charity information on page 1 of these financial
statements. The nature of the Charitys operations and principal activities are detailed in the Trustees,
Report.
The significant accounting policies applied in the preparation of these financial statements are set out
below. These policies have been consistendy applied to all years presented unless otherwise stated.
Accounting policies
2.1 Basis of preparatlon of financial statements
The financial statements have been prepared in accordance with the Charities SORP (FRS 1021
Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities
preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK
and Republic of Ireland (FRS 102) and the Companies Act 2006.
National Eczema Society meets the definition of a public benefit entity under FRS 102.
Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise
stated in the relevant accounting policy.
The Consolidated Statement of Financial Activities (SOFA) and Consolidated Balance Sheet
consolidate the financial statements of the Charity and its subsidiary undertaking. The results of the
subsidiary are consolidated on a line by line basis.
The financial statements are prepared in sterling which is the functional and presentational currency
of the Group and are rounded to the nearest pound.
2.2 Going concern
The Trustees have assessed the use of going concem and have considered possible events or
conditions that tllight cast signficant doubt on the ability of the Group to continue as a going concern.
The Trustees have made this assessment for a period of at least one year from the date of the
approval of these financial statements. The Trustees have concluded that there is a reasonable
expectation that the Group has adequate resources to continue in operational existence for Ihe
foreseeable future, and that no material uncertainties exist. The Group therefore continues to adopt
the going concem basis in preparing these financial statements.
Page 20

Docusign Envelope ID.. 9F2149Ftk322F4E6D-BA66-906B3BDECF3D
NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023
Accounting policies (continued)
2.3 Income
All income is recognised once the Group has entitlement to the income, it is probable that the income
will be received and the amount of income receivable can be measured reliably.
For donations and gift aid to be recognised the Group will have been notified of the amounts and the
settlement date in writing. If there are conditions attached lo the donation and this requires a level of
performance before entitlement can be obtained then income is deferred until those conditions are
fully met or the fuifilment of those conditions is within the control of the Group and it is probable that
they will be fulfilled.
The recognition of income from legacies is dependent on establishing enlillement, the probability of
receipt and the ability to estimate with sufficient accuracy the amount receivable. Evidence of
entitlement to a legacy exists when the Group has SLrfficient evidence that a gift has been left to them
(through knowledge of the exislence of a valid will and the death of the benefactor) and the executor
is satisfied that the property in question will not be required to satisfy claims in the estate. Receipt of
a legacy must be recognised when it is probable that it will be received and the fair value of the
amount receivable, which will generally be the expected cash amount to be distributed to the Group.
can be reliably measured.
Subscription income is received in full and recognised evenly over the course of the subscription. The
amount recognised in the Consolidated Statement of Financial Activities relates to the financial period
in question.
Income from trading activities includes income earned from fundraising events and trading activities
to raise funds for the Group. Income is received in exchange for supplwng goods and services in
order to raise funds and is recognised when entiuement has occurred.
Corporate membership income is received in full and recognised evenly over the course of the
membership. The amount recognised in the Consolidated Statement of Financial Activities relates to
the financial period in question.
2.4 Expenditure
All expenditure is accounted for on an accruals basis and has been classified under headings that
aggregate all costs related to the categories. Expenditure is recognised once there is a legal or
constructive obligation to transfer economic benefit to a Ihird party, il is probable that a transfer of
economic benefits will be required in settlement and the amount of the obligation can be measured
reliably. Expenditure is classified by activity- The costs of each activity are made up of the total of
direct costs and shared costs, including support costs involved in undertaking each activity. Direct
costs attributable to a single activity are allocated direcdy to that activty- Shared costs which
contribute to more than one activity and support costs which are not attributable to a single activity
are apportioned between those activities on a basis consistent with the use of resources. Central staff
costs are allocated on the basis of time spent. and depreciation charges allocated on the portion of
the asset's use.
Expenditure on charitable activities is incurred on diredy undertaking the activities which further the
Group's objectives, as well as any associated support costs.
All expenditure is indusive of irrecoverable VAT.
Page 21

Docusign Envelope ID.. 9F2149Ftk322F4E6D-BA66-906B3BDECF3D
NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023
Accounting policies (continued)
2.5 Interest receivable
Interest on funds held on deposit is included when receivable and the amount can be measured
reliably by the Group,. this is nonnally upon notification of the interest paid or payable by the institution
with whom the funds are deposited.
2.6 Taxation
The Charity is considered to pass the tests set out in Paragraph 1 Schedule 6 of the Finance Act
2010 and therefore il meets the definition of a charitable company for UK corporation tax purposes.
Accordingly, the Charity is FX)tentially exempt from taxation in respect of income or capital gains
received within categories covered by Chapter 3 Part 11 of the Corporation Tax Act 2010 or Section
256 of the Taxation of Chargeable Gains Acl 1992, to the extenl that such income or gains are
applied exclusively to charitable purposes.
2.7 Intangible assets and amortisation
Intangible assets costing £500 or more are capitalised and recognised when future economic
benefits are probable and the cost or value of the asset can be measured reliably.
Intangible assets are initially recognised at cost. After recognition, under the cost model, intangible
assets are measured at cost less any accumulated amortisation and any accumulated impairment
losses.
Amortisation is provided on intangible assets at rates calculated to write off the cost of each asset on
a straight-line basis over 3 years.
Assets under construction are not amortised until ready for use.
2.8 Tangible fixed assets and depreciation
Tangible fixed assets costing £500 or more are capitalised and recognised when future economic
benefits are probable and the cost or value of the asset can be measured reliably.
Tangible fixed assets are initially recognised at cost. After recognition, under the cost model, tangible
fixed assets are measured at cost less accumulated depreciation and any accumulated impairment
losses. All costs incurred to bring a tangible fixed asset inio its inlended working condition should be
included in the measurement of cost.
At each reporting date the Group assesses whether there is any indication of impaimient. If such
indication exists, the recoverable amount of the asset is determined to be the higher of its fair value
less costs to sell and its value in use. An impaimient loss is recognised where the carrwng amount
exceeds the recoverable amount.
Page 22

Docusign Envelope ID.. 9F2149Ftk322F4E6D-BA66-906B3BDECF3D
NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023
Accounting policies (continued)
2.8 Tangible fixed assets and depreciation (continued)
Depreciation is charged so as to allocate the cost of tangible fixed assets less their residual value
over their estimated useful lives. using the straight-line method.
Depreciation is provided on the followng bases-.
Leasehold improvements
Furniture and fittings
Office equipment
Computer equipment
over 10 years
over 10 years
over 10 years
over 3 years
2.9 Investments
The investment in the subsidiary company is valued at cost less provision for impairment.
2.10 Debtors
Trade and other debtors are recognised at the settlement amount after any trade discount offered.
Prepayments are valued at the amount prepaid net of any trade discounts due.
2.11 Cash al bank and in hand
Cash at bank and in hand includes cash and short-tem) highly liquid investments with a short maturity
of three months or less from the date of acquisition or opening of the deposit or similar account.
2.12 Liabilities and provisions
Liabilities are recognised when there is an obligation at the Balance Sheet date as a result of a past
event, it is probable that a transfer of economic benefit wll be required in settlement, and the amount
of the settlement can be estimated reliably.
Liabilities are recognised at the amount that the Group anticipates it will pay to settle the debt or the
amount it has received as adVan￿d payments for the goods or ServI￿S it rnust provide.
Provisions are measured at the best estimate of the amounts required to settle the obligalion. Where
the effect of the time value of money is material, the provision is based on the present value of those
amounts, discounted at the prfrtax discount rate that refleGls the risks specific to the liability- The
unwinding of the discount is recognised in the Consolidated Slatement of Financial Activities as a
finance cost.
Page 23

Docusign Envelope ID.. 9F2149Ftk322F4E6D-BA66-906B3BDECF3D
NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023
Accounting policies (continued)
2.13 Financial instruments
The Group only holds basic Financial Instruments. The financial assets and financial liabilities of the
Group are as follows..
Debtors
other debtors are basic financial instrumer7ts and are debt instruments measured at
amortised cost as detailed in Note 17.
Cash al bank- is classified as a basic financial instnJment and is measured at face value.
Liabilities
accruals are classified as financial instruments, and are measured at amortised cost as
detailed in Notes 18 and 19.
2.14 Operatlng leases
Rentals paid under operating leases are charged to the Consolidated Statement of Financial
Activities on a straight line basis over the lease term.
2.15 Pensions
Through its past participation. the Group has a liability to a pension scheme called the Series 3
Growth Plan, which closed in 2013. Since then, the Group has participated in a defined contribution
pension scheme for employees. operated by workplace pension provider TPT.
The Group is part of the Series 3 Growth Plan which is a multi-employer pension Scheme which
Closed in 2013. The Scheme administrators have confirmed that it is not possible to separately
identify the assets and liabilities of participating employers on a consistent and reasonable basis. The
assets of the Scheme are co-mingled for investment purposes and benefits are paid from total
Scheme assets. A deficit reduction plan has been agreed.
The Group accounts for its participation in this Plan as a defined contribution plan, as there is
insufficient information available to account for this as a defined benefit plan, as the share of its
assets and liabilities cannot be identified.
To avoid crystallizing an immediate payThent of the apparent under-funding in the Series 3 Scheme,
the Group is participating in the Series 3 Recovery Plan and the liability is included in Notes 18 and
19. The Group recognises its liability to make payments lo fund the deficit relaling lo past setvice
under an agreement to make those payTnents. It recognises the full liability for the present value of
contributions payable that results from the agreement for funding the multi employer plan.
The Group also parbcipates in a defined contribution pension scheme for its employees. The Group
pays fixed contributions into a separate scheme. Once the defined contribution payments have been
made, the Group has no further payTnent obligations in respect of this scheme. The Gontributions are
recognised as an expense in the Consolidated Statement of Financial Activities as they fall due.
Page 24

Docusign Envelope ID.. 9F2149Ftk322F4E6D-BA66-906B3BDECF3D
NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023
Accounting policies (continued)
2.16 Fund accounting
General funds are unrestricted funds which are available for use at the discretion of the Trustees in
furtherance of the general objectives of the Group and which have not been designated for other
purposes.
Designated funds comprise unrestricted funds that have been set aside by the Trustees for particular
purposes. The aim and use of each designated fund is set out in the notes to the financial
statements.
Restricted funds are funds which are to be used in accordance with specific restrictions imposed by
donors or which have been raised by the Group for particular purposes. The costs of raising and
administering such funds are charged against the specific fund. The aim and use of each restricled
fund is set out in the notes to the financial statements.
Investment income. gains and losses are alli)cated to the appropriate fund.
Critical accounting estimates and areas of judgement
Estimates and judgements are continually evaluated and are based on historical experience and other
factors, including expectations of future events that are believed to be reasonable under the
circumstances.
Critical accounting estimates and assumptions:
The Group makes estimates and assumptions conceming the future. The resulting accounting estimates
and assumptions will, by definition. seldom equal the related actual results. The estimates and
assumptions that have a significant risk of causing a material adjustment to the carrying amounts of
assets and liabilities within the next financial year are listed below.
Allocation of support costs
Legacy income recognition
Depreciation rates for tangible fixed assets
Useful economic lives of assets
The discount rate used in valuing the year-end Pension Scheme deficit.
Page 25

Docusign Envelope ID.. 9F2149Ftk322F4E6D-BA66-906B3BDECF3D
NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023
Income from donations and legacies
Unrestricted Restricted
funds
funds
2023
2023
Total
funds
2023
Donations and similar income
Legacies
Subscriptions
Gift aid
205,431
110,610
141.813
23,304
205,431
110,610
141,813
23.304
Total 2023
481,158
481,158
Unrestricted
funds
2022
Restricted
funds
2022
Total
funds
2022
Donations and similar income
132.853
24,706
143,952
20.551
5.013
137.866
24,706
143,952
20.551
Legacies
Subscriptions
Gift aid
Total 2022
322.062
5.013
327,075
Page 26

Docusign Envelope ID.. 9F2149Ftk322F4E6D-BA66-906B3BDECF3D
NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023
Income from other trading activities
Income from fundraising events
Unrestricted
funds
2023
Total
funds
2023
Other corporate income
Other activities
2.896
2,836
2,896
2,836
Total 2023
5,732
5,732
Unreslricted
funds
2022
Total
funds
2022
Other corporate income
Other activities
6,265
3,940
6,265
3,940
Total 2022
10,205
10,205
Income from non charitable trading activities
Unrestricted
funds
2023
Tolal
funds
2023
Trading subsidiary
2,965
2,965
Unrestricted
funds
2022
Total
funds
2022
Trading subsidiary
4,109
4,109
Page 27

Docusign Envelope ID.. 9F2149Ftk322F4E6D-BA66-906B3BDECF3D
NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023
Income from investments
Unrestricted
funds
2023
Total
funds
2023
Bank interest receivable
7,397
7.397
Unrestricted
funds
2022
Total
funds
2022
Bank interest receivable
1,432
1,432
Page 28

Docusign Envelope ID.. 9F2149Ftk322F4E6D-BA66-906B3BDECF3D
NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023
Expenditure on raising funds
2023
2022
Fundraising ¢ost$
Direct costs
65,707
5,604
59.330
5.574
Support costs
71,311
64.904
Analysis of support costs - fundraising costs
2023
2022
Staff costs
1,912
382
1,735
562
Depreciation
Premises costs
Carriage and postage
HCP services and fees
Professional fees
Bought-in services
Website, database and computing
Other costs
Governance costs
728
116
727
289
33
349
41
370
33
583
931
344
712
835
496
5,604
5,574
2023
2022
Trading costs
Trading subsidiary- Direct costs
In both the current and previous financial years all Expenditure on raising funds was from Unrestricted
funds.
Page 29

Docusign Envelope ID.. 9F2149Ftk322F4E6D-BA66-906B3BDECF3D
NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023
Analysis of expenditure on charitable activities - by fund
Unrestricted
funds
2023
Tolal
2023
Helpline
Membership ServI￿S
Information services
110.547
181,415
114,283
110,547
181,415
114,283
Total 2023
406,245
406,245
Unrestricted
funds
2022
Total
2022
Helpline
Membership services
Information services
100,310
174,303
74,240
100,310
174,303
74,240
Total 2022
348.853
348.853
Page 30

Docusign Envelope ID.. 9F2149Ftk322F4E6D-BA66-906B3BDECF3D
NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023
Analysis of expenditure on charitable activities - by type
Activities
undertaken
directly
2023
Support
costs
2023
Total
funds
2023
Helpline
Membership SeNi￿S
Information services
60,804
102.860
73,335
49,743
78.555
40,948
110,547
181,415
114.283
Total 2023
236,999
169,246
406,245
Activities
undertaken
directly
2022
Support
costs
2022
Total
funds
2022
Helpline
Membership ServI￿S
Information services
56,071
96.182
33,519
44,239
78.121
40.721
100,310
174.303
74,240
Total 2022
185.772
163.081
348.853
Page 31

Docusign Envelope ID.. 9F2149Ftk322F4E6D-BA66-906B3BDECF3D
NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023
Analysis of expenditure on charitable activities - by type (continued)
Analysis of support costs
Total
funds
2023
Total
funds
2022
Staff costs
Depreciation
Premises costs
55,947
11,165
21,302
3,399
13,130
1,205
20,833
1,750
27,930
11,619
966
50.750
16,435
21,266
8,468
10,838
962
Carriage and postage
Professional fees
Bought-in services
Website, database and computing
Insurance
17,050
Other costs
27.236
10,076
Governance costs
HCP services and fees
169.246
163,081
10. Governance costs
2023
2022
Independent Examinerfs remuneration
staff training
Insurance
2.000
2,065
5,789
2,000
6.681
1.150
50
Recruitment
Room hire & Conference expenses
Trustees expenses
Travel, hotels & subsistence
General office expenses
1,498
198
639
245
26
96
12,017
10,420
Total Governance costs above comprise £398 (2022 - £344) of Expenditure on raising funds and £11,619
(2022 - £10,076) of Expenditure on charitable activities.
Page 32

Docusign Envelope ID.. 9F2149Ftk322F4E6D-BA66-906B3BDECF3D
NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023
11. Auditors, and Independent examinerfs remuneration
2023
2022
Independent Examinerfs remuneration - Examination of the financial
stalements
5,250
5,010
(3.010)
Independent Examinerfs remuneration - prior year over-accrual
12.
staff costs
Group
2023
Group
2022
Charity
2023
Charity
2022
Wages and salaries
Social security costs
Pension costs
212,525
19,710
10,327
203.865
18.600
8.470
212,525
19,710
10,327
203,865
18.600
8,470
242,562
230.935
242,562
230,935
The average number of persons employed by the Charity during the year was as follows..
Group
2023
No.
Group
2022
No.
Direct charitable activities
Fundraising and communication
Support and governance
The number of employees whose employee benefits (excluding employer pension costs) exceeded
£60,000 was:
Group
2023
No.
Group
2022
No.
In the band £60,001- £70,000
The total amount of employee benefits, including employers national insurance and pension
contributions, received by Key Management Personnel is £138,823 (2022 - £72,726). The Charity
considers its Key Management Personnel comprise the Trustees and the Chief Executive Officèr and
deputy CEO.
Page 33

Docusign Envelope ID.. 9F2149Ftk322F4E6D-BA66-906B3BDECF3D
NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023
13. Trustees. remuneration and expenses
During the year, no Trustees received any remuneration or other benefils (2022 - £NIL).
During the year ended 31 December 2023. expenses totalling £499 were reimbursed or paid directly to 2
trustees (2022 - £198} in relation to travel and conference costs.
14. Intangible assets
Group and Charity
Website
Cost
At 1 January 2023
Additions
20,988
2,021
At 31 December 2023
23,009
Amortisation
At 1 January 2023
Charge for the year
19,152
2.395
At 31 December 2023
21,547
Net book value
At 31 December 2023
1,462
At 31 December 2022
1,836
Page 34

Docusign Envelope ID.. 9F2149Ftk322F4E6D-BA66-906B3BDECF3D
NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023
15. Tangible fixed assets
Group and Charity
Leasehold
Fumitu
improvements and fixtures
Office
equipment
Computer
equipment
Tolal
Cost or valuation
At 1 January 2023
Additions
41,470
2,493
3.873
24,189
2.000
72,025
2.000
At 31 December 2023
41,470
2,493
3,873
26,189
74,025
Depreciation
At 1 January 2023
Charge for the year
30,078
4,152
1,929
249
2.693
370
19,440
4,381
54,140
9,152
At 31 December 2023
34,230
2,178
3.063
23,821
63,292
Net book value
At 31 December 2023
7,240
315
810
2,368
10,733
At 31 December 2022
11.392
565
1,179
4,749
17,885
Page 35

Docusign Envelope ID.. 9F2149Ftk322F4E6D-BA66-906B3BDECF3D
NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023
16. Fixed asset investments
Investment
in
subsldlary
company
Charity
Cost or valuation
At 1 January 2023
100
At 31 December 2023
100
Principal subsidiaries
The following was a subsidiary undertaking of the Charity.
Name
Company Registered office or
number
principal place of
business
Holding Included in
consolidation
Eczema Trading Limited
06895048 11 Murray Street,
London, NW19RE
1000/0 Yes
The financial results of the subsidiary for the year were:
Name
Income
Expenditure
Profit for
the year
Net assets
Eczema Trading Limited
67.816
(5,006)
62,810
33,385
The results of Eczema Trading Limited are included in these consolidated accounts. Eczema Trading
Limited did not meet the audit threshold and therefore did not require an audit for the year ended 31
December 2023. The reported surplus relates to intercompany management Gharges and minimal
advertising and corporate membership revenue.
For the year ended 31 December 2023. Corporate memberships. the advertising revenue from our
membership magazine. together with limited income from company supporters. is accounted for in
Eczema Trading Limited.
Page 36

Docusign Envelope ID.. 9F2149Ftk322F4E6D-BA66-906B3BDECF3D
NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023
17. Debtors
Group
2023
Group
2022
Charity
2023
Charity
2022
Due within one year
Trade debtors
Amounts owed by group undertakings
Other debtors
Prepayments and accrued income
20,762
26,160
2,762
83,935
50,622
17.522
93,367
26.219
13,066
50,622
17.522
26.219
13,066
88,906
65.445
154,841
132,652
18. Creditors: Amounts falling due within one year
Group
2023
Group
2022
Charity
2023
Charity
2022
Trade creditors
5.127
15,401
4,395
133.850
5,680
12,616
6.995
91,649
5.127
15,401
4,395
90.868
5,680
12,616
6.995
89,849
Other taxation and social security
Other creditors
Accruals and deferred income
158,773
116.940
115,791
115.140
Group
2023
Group
2022
Charity
2023
Charity
2022
Deferred income
Deferred income at 1 January
Resources deferred during the year
Amounts released from previous periods
79,880
181,318
(150,585)
75,422
78,080
{73.622)
78,080
99,318
{77,235)
73,622
78,080
173.622)
Deferred income at 31 December
110,613
79.880
100,163
78.080
Deferred income consists of membership income relating to future periods.
Page 37

Docusign Envelope ID.. 9F2149Ftk322F4E6D-BA66-906B3BDECF3D
NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023
19. Creditors: Amounts falling due after more than one year
Group
2023
Group
2022
Charity
2023
Charity
2022
Pension Scheme deficit
360
4.264
360
4.264
Through its past participation. the Group has a liability to a pension scheme called the Series 3 Gr0￿h
Plan, which closed in 2013. Since then, the Group has participated in a defined contribution pension
scheme for employees. operated by workplace pension provider TPT.
The Charity is participating in a recovery plan to eliminate its Series 3 scheme deficit over a ten year
period. The Pensions Trust. the scheme administrator. has however advised that the amounl of employer
debt on the alternative of withdrawal from the Series 3 scheme has been estimated by actuaries to have
been £200,161 as at 31 December 2016. As the Charity intends to continue participating in the recovery
plan, no provision has been made for this potential withdrawal debt however, Ihe Society accounted for
the present value of all remaining contributions under Ihe recovery plan in the 2017 accounts at their
present value of £120.000, as advised by the scheme administrator. This liability has been adjusled
annually to unwind the relevant discount applied.
In order to meet their share of the shortfall. the Charity has been asked lo pay additional contributions to
the scheme until 2025. A full actuarial valuation was carried out by the actuaries at 30 September 2017
and the funding shortfall calculated al that date gave rise to a remeasurement reduction of £15,624 in the
deficit as at 31 December 2018. The deficit of the scheme is £4,556, (2022 - £8,587) at 31 December
2023. The payment by the Charty in the year was £4,324, (2022 - £7, 105) with an interest payment of
£311 {2022- £130) and a revalualion gain of £8 (2022- £317).
In addition. the Charity elected to switch, with effect from 1 October 2013. from Series 3 to Series 4, a
defined contribution scheme. The pension cost in the accounts represents amounts payable by the charity
as ordinary employer contributions to the Series 4 defined contribLrtion fund.
During the year employer contributions of £10,327 (2022 - £8,470). interest of £311 (2022 £130).
actuarial Igains)Aosses of £8 (2022 £317) and remeasurements for amendments to the conlribulion
schedule of £Nil (2022 £Nil) have been charged to the Consolidated Statement of Financial Activities,
along wth scheme costs of £3.625 (2021.. £Nil). There were no accrued contributions at 31 December
2023 (2022 £NIL) but there is a liability of £4,566 (2022 £8,587) for fulure contributions under Ihe
Series 3 Recovery Plan. Of this £360 (2022 - £4,323) is reported in Creditors.. Amounts falling due within
one year as part of Other creditors and £360. (2022- £4,264) is reported in Creditors.. Amounts falling due
after more then one year.
Page 38

Docusign Envelope ID.. 9F2149Ftk322F4E6D-BA66-906B3BDECF3D
NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023
20. Statement of funds
Statement of funds - current year
Balance at
31
December
2023
Balance at 1
January
2023
Transfers
inl(out)
Gainsl
{Losses)
Income Expenditure
Unrestricted
funds
Designated
funds
Fixed asset fund
Pension reserve
Research fund
19,721
(8,587)
110,000
(10,839)
(5,579)
4,021
9,591
12,903
(4,567)
110,000
121.134
(16.418)
13.612
118.336
General funds
General funds
523.185
497.252
(461.145)
(13.6121
545.680
Total
Unrestricted
funds
644.319
497.252
(477.563)
664,016
Restricted
funds
Restricted Funds
all funds
6,751
6,751
Total of funds
651,070
497,252
(477,563)
670,767
Page 39

Docusign Envelope ID.. 9F2149Ftk322F4E6D-BA66-906B3BDECF3D
NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023
20. Statement of funds (continued)
Statement of funds - prior year
Balance at
31
December
2022
Balance at
1 January
2022
Transfers
inlout
Gainsl
(Losses)
Income Expenditure
Unrestricted
funds
Designated
funds
Fixed asset fund
Pension reserve
Research fund
36.718
(15,879)
(16.997)
(3.755)
19.721
{8,587}
110,000
10,730
110.000
317
20,839
(20,752)
120,730
317
121,134
General funds
General funds
699,114
337,808
(393,007) 1120,730)
523,185
Total
Unrestricted
funds
719,953
337,808
(413.759)
317
644,319
Restricted
funds
Research
1,738
5,013
6,751
Totsl of funds
721,691
342,821
(413.759)
317
651,070
Page 40

Docusign Envelope ID.. 9F2149Ftk322F4E6D-BA66-906B3BDECF3D
NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023
20. Statement of funds (continued)
Desi
nated funds
The Pension reserve has been established to show the future pension deficit payments in regards to a
defined benefit pension scheme. This pension scheme is being treated as a defined contribution pension
scheme as a reliable estimate cannot be made of the liability at the year end. The transfer of £9,591, was
made to separate the deficit payments due as at 31 December 2023 from the Unrestricted general fund.
Actuarial gains l (losses) are charged to this fund as they arise.
The Fixed asset fund has been established to reflect the funds tied up in Tangible and Intangible fixed
assets and agrees back to the Net Book Value presented on the Consolidated Balance Sheet.
Depreciation is charged to this fund as expenditure.
The Research fund has been established to designate funds for research into the causes and treatment
of eczema, which is a key aim of the Society. The Society will provide grants to researchers on a periodic
basis and it is necessary to designate sufficient reserves to fund the expected grant costs. The fund is
expected to be ulilised and grants avRrded commencing in the financial year to 31 December 2024.
Unrestricted funds
General funds reflects funds which are available for use at the discretion of the Trustees in furtherance of
the general objectives of the Charity and vthich have not been designated for other purposes.
Restricted funds
The Research fund exists to provide resources for research into the causes of eczema, with the aim of
developing more effective treatments or a cure.
21. Analysis of net assets between funds
Analysis of net assets between funds - current year
Unrestricted
funds
2023
Restricted
funds
2023
Total
funds
2023
Tangible fixed assets
Intangible fixed assets
Current assets
Creditors due within one year
Creditors due in more than one year
10.733
1.462
810,954
(158.773)
{360)
10,733
1,462
817.705
(158,773)
{360)
6,751
Total
664.016
6.751
670,767
Page 41

Docusign Envelope ID.. 9F2149Ftk322F4E6D-BA66-906B3BDECF3D
NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023
21. Analysis of net assets between funds (continued)
Analysis of net assets between funds - prior year
Unrestricted
funds
2022
Rèstricted
funds
2022
Total
funds
2022
Tangible fixed assets
Intangible fixed assets
Current assets
Creditors due within one year
Creditors due in more than one year
17,885
1.836
745,802
(116,940)
(4,264)
17,885
1.836
752,553
1116,940}
{4,264)
6,751
Total
644.319
6.751
651.070
22. Reconciliation of net movement in funds to net cash flow from operating activities
Group
2023
Group
2022
Net incomelexpenditure for Ihe year (as per Ststemenl of Financial
Activities)
19,690
170.938)
Adjustments for:
Depreciation charges
Amortisation charges
Losses on investments
9,152
2,395
(7,397)
{53,516)
60.041
10.001
6.996
{1,432)
94.070
(2,598}
317
Decreasel(increasel in debtors
Increasel(decreasel in creditors
Actuarual Gainsl {loss) on pension
Net cash provided by operating activities
30.365
36,416
Page 42

Docusign Envelope ID.. 9F2149Ftk322F4E6D-BA66-906B3BDECF3D
NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023
23. Analysis of cash and cash equivalents
Group
2023
Group
2022
Cash in hand
728,799
687,108
Total cash and cash equivalents
728,799
687.108
Analysis of changes in net debt
At1
January
2023 Cash flows
At31
December
2023
Cash at bank and in hand
687,108
41,691
728,799
687.108
41.691
728.799
25. Operating lease commitments
At 31 December 2023 the Group and the Charty had commitments to make future minimum lease
paymenls under non-cancellable operating leases as follows:
Group
2023
Group
2022
Charity
2023
Charity
2022
Not later than 1 year
Later than 1 year and not later than 5 years
21,000
4,333
21,000
25,333
21,000
4,333
21,000
25,333
25,333
46.333
25,333
46.333
The following lease payments have been recognised as an expense in the Statement of Financial
Activities..
Group
2023
Group
2022
Charity
2023
Charity
2022
Operating lease rentals
21,000
21,000
21,000
21,000
Page 43

Docusign Envelope ID.. 9F2149Ftk322F4E6D-BA66-906B3BDECF3D
NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023
26.
Related party transactions
In the year ended 31 D￿mber 2023, unrestricted donations of £120 (2022 - £1, 758) were made by the
Trustees of the Charity.
Page 44